Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.1450 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharmather Hldgs Ltd

< Previous 1 2 3 4 Next >
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
KetaVault™ to Provide Partners Unprecedented Access to PharmaTher's Extensive Regulatory, Manufacturing, and Clinical Ketamine Data, Aiming to Expedite New Therapies and Market Entry 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Receives US FDA Approval Goal Date for Ketamine
The Assigned FDA Approval Goal Date is June 4, 2025 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
Expecting FDA approval of Ketamine in Q2-2025Solving the shortage problem of Ketamine and unlocking its pharmaceutical potentialToronto, Ontario--(Newsfile Corp. -... 
Via Newsfile
Exposures Product Safety
PharmaTher Provides Update on FDA New Drug Application for Ketamine
PharmaTher expects to submit the MINOR AMENDMENT to the CRL by end-February 2025 and expects a new approval date for a Q2-2025 FDA approval of ketamine 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher CEO Issues Letter to Shareholders
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
The FDA Assigned Goal Date is October 29, 2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
PharmaTher Provides Update for Expected FDA Approval of Ketamine
Assigned FDA approval goal date of April 29, 2024, is still on track 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product. 
Via Benzinga
Exposures Product Safety
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.